Current pharmacotherapy of depression – focused on multimodal/multifunctional antidepressants

E. Češková
DOI: https://doi.org/10.1080/14656566.2016.1219340
2016-08-10
Expert Opinion on Pharmacotherapy
Abstract:Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030.
What problem does this paper attempt to address?